GC Corp (GC), formerly Green Cross Holdings, is a biopharmaceutical company. It carries out the manufacturing and distribution of pharmaceuticals and quasi-drugs, medical instruments, sanitary products, foodstuffs and additives, and chemical products. The company also focuses to develop innovative drugs including cell therapy products and orphan drugs. It develops and manufactures diagnostic reagents, test kits and nutritional injections including placenta injections. GC provides non-face to face treatment, hospital and clinic reservations and real-time monitoring services through its digital healthcare platform. It also provides real estate development, sale and rental services. GC is headquartered in Yongin, Gyeonggi, South Korea.
Headquarters
South Korea
Address
107, Ihyeon-Ro 30beon-Gil, Giheung-Gu, Yongin, 16924
Website
www.gccorp.com
Telephone
82 31 2609300
No of Employees
170
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
005250 (KRX)
Revenue (2022)
$1.6B
13%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-40.6%
(2022 vs 2021)
Market Cap*
$534.8M
Net Profit Margin (2022)
XYZ
-47.3%
(2022 vs 2021)
* As of and is in US$
GC Corp premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Quasi Drugs | Non Face to Face Treatment |
| Medical Instruments | Hospital and Clinic Reservations |
| Sanitary Products | Real Time Monitoring Services |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In February, GC Green Cross signed an asset purchase agreement with Catalyst Biosciences for a pipeline related to rare blood clotting diseases. |
| 2023 | Contracts/Agreements | In February, GC Green Cross entered into a joint sales partnership for domestic sales and marketing of Plavix Tab. |
| 2022 | Contracts/Agreements | In December, GC Green Cross Wellbeing signed a technology transfer and joint development contract for 'GCWB204', a cancer cachexia treatment candidate with M Therapharma. |
Competitor Comparison
| Key Parameters | GC Corp | McKesson Corp | Celltrion Inc | Chong Kun Dang Pharmaceutical Corp. | INFINITT Healthcare Co., Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | United States of America | South Korea | South Korea | South Korea |
| City | Yongin | Irving | Incheon | Seoul | Seoul |
| State/Province | - | Texas | - | - | - |
| No. of Employees | 170 | 45,000 | 1,074 | 1,904 | 257 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Heo Ilseop | Chairman | Executive Board | - | - |
| Heo Joon Heo | Chief Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward